Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Morris

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|May 1, 2013
High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcomaMiriam Lynn, Yuexiang Wang, Jaime Slater, et al.
BJU International|March 5, 2014
Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survivalCampbell Tait, David Moore, Clare Hodgson, et al.
BJU International|September 16, 2010
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trialNicholas D James, Armelle Caty, Heather Payne, et al.
Scandinavian Journal of Urology and Nephrology|November 30, 2006
Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 yearsPeter Iversen, Jan-Erik Johansson, Pär Lodding, et al.
The Prostate|January 29, 2011
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancerDonald L Trump, Heather Payne, Kurt Miller, et al.
Genes, Chromosomes & Cancer|August 21, 2014
Identification of an MLL4-GPS2 fusion as an oncogenic driver of undifferentiated spindle cell sarcoma in a childElaine O'Meara, Deirdre Stack, Susan Phelan, et al.
Journal of Sports Sciences|September 21, 2023
Exercise-induced hypohydration impairs 3 km treadmill-running performance in temperate conditionsMark P Funnell, Daniel Embleton, Thomas Morris, et al.
Hematology/Oncology and Stem Cell Therapy|November 23, 2020
Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi ArabiaNour AlMozain, Ayman Mashi, Qasem Alneami, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Dementia Care Research and Psychosocial FactorsDeborah Brooks, Deepa Sriram, Rachel Brimelow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancerKarim Fizazi, Karim S Fizazi, Celestia S Higano, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|May 1, 2013
High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcomaMiriam Lynn, Yuexiang Wang, Jaime Slater, et al.
BJU International|March 5, 2014
Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survivalCampbell Tait, David Moore, Clare Hodgson, et al.
BJU International|September 16, 2010
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trialNicholas D James, Armelle Caty, Heather Payne, et al.
Scandinavian Journal of Urology and Nephrology|November 30, 2006
Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 yearsPeter Iversen, Jan-Erik Johansson, Pär Lodding, et al.
The Prostate|January 29, 2011
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancerDonald L Trump, Heather Payne, Kurt Miller, et al.
Genes, Chromosomes & Cancer|August 21, 2014
Identification of an MLL4-GPS2 fusion as an oncogenic driver of undifferentiated spindle cell sarcoma in a childElaine O'Meara, Deirdre Stack, Susan Phelan, et al.
Journal of Sports Sciences|September 21, 2023
Exercise-induced hypohydration impairs 3 km treadmill-running performance in temperate conditionsMark P Funnell, Daniel Embleton, Thomas Morris, et al.
Hematology/Oncology and Stem Cell Therapy|November 23, 2020
Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi ArabiaNour AlMozain, Ayman Mashi, Qasem Alneami, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Dementia Care Research and Psychosocial FactorsDeborah Brooks, Deepa Sriram, Rachel Brimelow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancerKarim Fizazi, Karim S Fizazi, Celestia S Higano, et al.
Pageof 9